Klaus Krueger

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial

Frank Buttgereit, G Doering, Achim Schaeffler et al. · The Lancet · 2008 · 389 citations

Rheumatoid Disorder, Rheumatology, Medicine +8

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

Gerd R Burmester, Frank Buttgereit, Corrado Bernasconi et al. · The Lancet · 2020 · 121 citations · Full text

Rheumatoid Disorder, Rheumatology, Low Disease Activity +8

Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis

Frank Buttgereit, A. Schaeffler, S Witte et al. · Annals of the Rheumatic Diseases · 2010 · 109 citations · Full text

Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment

Jürgen Rech, Axel J. Hueber, Stephanie Finzel et al. · Annals of the Rheumatic Diseases · 2015 · 89 citations · Full text

Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions

Stefan Kleinert, H-P Tony, Klaus Krueger et al. · Annals of the Rheumatic Diseases · 2012 · 71 citations · Full text